feed,title,long_url,short_url
Benzinga,"Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with BetalutinÂ® in R/R Follicular Lymphoma",https://www.benzinga.com/pressreleases/21/02/n19720542/nordic-nanovector-sees-significant-improvement-in-patient-recruitment-rate-in-paradigme-its-single,https://j.mp/3dowstm
